NovelStem International Corp. (NSTM)
USD 0.01
(23.46%)
USD 0.01
(23.46%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 12 Thousand USD | 0.0% |
| 2022 | 12 Thousand USD | 0.0% |
| 2021 | - USD | 0.0% |
| 2020 | - USD | 0.0% |
| 2013 | -1.7 Million USD | -377.47% |
| 2012 | 613.01 Thousand USD | 282.6% |
| 2011 | -335.71 Thousand USD | 75.04% |
| 2010 | -1.34 Million USD | -106.01% |
| 2009 | 22.36 Million USD | -7.49% |
| 2008 | 24.17 Million USD | -20.77% |
| 2007 | 30.51 Million USD | -10.17% |
| 2006 | 33.96 Million USD | 20.88% |
| 2005 | 28.09 Million USD | 74.96% |
| 2004 | 16.06 Million USD | 9.54% |
| 2003 | 14.66 Million USD | -14.66% |
| 2002 | 17.18 Million USD | -3.67% |
| 2001 | 17.83 Million USD | 15.3% |
| 2000 | 15.46 Million USD | 120.98% |
| 1999 | 7 Million USD | 4.48% |
| 1998 | 6.7 Million USD | 15.52% |
| 1997 | 5.8 Million USD | 114.81% |
| 1996 | 2.7 Million USD | 145.45% |
| 1995 | 1.1 Million USD | 120.0% |
| 1994 | 500 Thousand USD | 400.0% |
| 1993 | 100 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 3000.00 USD | 0.0% |
| 2024 Q1 | 3000.00 USD | 0.0% |
| 2023 Q1 | - USD | -100.0% |
| 2023 FY | 12 Thousand USD | 0.0% |
| 2023 Q2 | - USD | 0.0% |
| 2023 Q4 | 3000.00 USD | -66.67% |
| 2023 Q3 | 9000.00 USD | 0.0% |
| 2022 Q3 | - USD | 0.0% |
| 2022 FY | 12 Thousand USD | 0.0% |
| 2022 Q1 | - USD | 0.0% |
| 2022 Q2 | - USD | 0.0% |
| 2022 Q4 | 12 Thousand USD | 0.0% |
| 2021 Q4 | - USD | 0.0% |
| 2021 Q3 | - USD | 0.0% |
| 2021 Q2 | - USD | 0.0% |
| 2021 FY | - USD | 0.0% |
| 2021 Q1 | - USD | 0.0% |
| 2020 FY | - USD | 0.0% |
| 2013 Q2 | -441.91 Thousand USD | -8.4% |
| 2013 Q3 | -385.22 Thousand USD | 12.83% |
| 2013 Q4 | -444.96 Thousand USD | -15.51% |
| 2013 Q1 | -407.68 Thousand USD | -319.26% |
| 2013 FY | -1.7 Million USD | -377.47% |
| 2012 FY | 613.01 Thousand USD | 282.6% |
| 2012 Q3 | 96.03 Thousand USD | -38.52% |
| 2012 Q1 | 709.87 Thousand USD | -13.69% |
| 2012 Q4 | 185.93 Thousand USD | 93.62% |
| 2012 Q2 | 156.21 Thousand USD | -77.99% |
| 2011 FY | -335.71 Thousand USD | 75.04% |
| 2011 Q3 | 860.62 Thousand USD | -22.87% |
| 2011 Q2 | 1.11 Million USD | 14.93% |
| 2011 Q1 | 970.87 Thousand USD | 107.07% |
| 2011 Q4 | 822.45 Thousand USD | -4.43% |
| 2010 Q2 | 6.49 Million USD | 27.42% |
| 2010 Q3 | 6.12 Million USD | -5.78% |
| 2010 Q4 | -13.72 Million USD | -324.18% |
| 2010 FY | -1.34 Million USD | -106.01% |
| 2010 Q1 | 5.09 Million USD | -24.02% |
| 2009 Q3 | 5.23 Million USD | -14.59% |
| 2009 Q2 | 6.13 Million USD | 43.32% |
| 2009 FY | 22.36 Million USD | -7.49% |
| 2009 Q1 | 4.27 Million USD | -22.92% |
| 2009 Q4 | 6.71 Million USD | 28.12% |
| 2008 FY | 24.17 Million USD | -20.77% |
| 2008 Q4 | 5.55 Million USD | -5.73% |
| 2008 Q3 | 5.88 Million USD | -29.05% |
| 2008 Q2 | 8.3 Million USD | 11.1% |
| 2008 Q1 | 7.47 Million USD | -9.62% |
| 2007 Q2 | 9.59 Million USD | 17.57% |
| 2007 Q1 | 8.15 Million USD | -17.11% |
| 2007 Q4 | 8.26 Million USD | 6.2% |
| 2007 FY | 30.51 Million USD | -10.17% |
| 2007 Q3 | 7.78 Million USD | -18.84% |
| 2006 Q3 | 7.93 Million USD | -19.27% |
| 2006 FY | 33.96 Million USD | 20.88% |
| 2006 Q4 | 9.84 Million USD | 24.0% |
| 2006 Q2 | 9.83 Million USD | 35.87% |
| 2006 Q1 | 7.23 Million USD | -15.02% |
| 2005 Q3 | 6.42 Million USD | -10.32% |
| 2005 FY | 28.09 Million USD | 74.96% |
| 2005 Q4 | 8.51 Million USD | 32.49% |
| 2005 Q2 | 7.16 Million USD | 19.7% |
| 2005 Q1 | 5.98 Million USD | 425.97% |
| 2004 Q1 | 4.83 Million USD | 126.79% |
| 2004 Q2 | 5.18 Million USD | 7.25% |
| 2004 Q4 | 1.13 Million USD | -76.79% |
| 2004 Q3 | 4.9 Million USD | -5.37% |
| 2004 FY | 16.06 Million USD | 9.54% |
| 2003 Q2 | 3.94 Million USD | -1.12% |
| 2003 Q3 | 4.58 Million USD | 16.13% |
| 2003 Q4 | 2.13 Million USD | -53.54% |
| 2003 FY | 14.66 Million USD | -14.66% |
| 2003 Q1 | 3.99 Million USD | -5.67% |
| 2002 Q1 | 4.46 Million USD | 13.94% |
| 2002 Q2 | 5.05 Million USD | 13.1% |
| 2002 Q4 | 4.23 Million USD | 23.75% |
| 2002 Q3 | 3.42 Million USD | -32.31% |
| 2002 FY | 17.18 Million USD | -3.67% |
| 2001 Q4 | 3.92 Million USD | -14.97% |
| 2001 FY | 17.83 Million USD | 15.3% |
| 2001 Q2 | 5.05 Million USD | 14.02% |
| 2001 Q1 | 4.43 Million USD | 20.77% |
| 2001 Q3 | 4.61 Million USD | -8.72% |
| 2000 Q4 | 3.67 Million USD | -19.99% |
| 2000 Q2 | 4.11 Million USD | 26.7% |
| 2000 FY | 15.46 Million USD | 120.98% |
| 2000 Q1 | 3.24 Million USD | 24.94% |
| 2000 Q3 | 4.58 Million USD | 11.47% |
| 1999 Q1 | 1.1 Million USD | -45.0% |
| 1999 Q4 | 2.6 Million USD | 13.04% |
| 1999 Q3 | 2.3 Million USD | 76.92% |
| 1999 Q2 | 1.3 Million USD | 18.18% |
| 1999 FY | 7 Million USD | 4.48% |
| 1998 FY | 6.7 Million USD | 15.52% |
| 1998 Q3 | 1.3 Million USD | -13.33% |
| 1998 Q2 | 1.5 Million USD | -21.05% |
| 1998 Q1 | 1.9 Million USD | 137.5% |
| 1998 Q4 | 2 Million USD | 53.85% |
| 1997 Q4 | 800 Thousand USD | -33.33% |
| 1997 Q3 | 1.2 Million USD | -60.0% |
| 1997 Q2 | 3 Million USD | 233.33% |
| 1997 Q1 | 900 Thousand USD | 125.0% |
| 1997 FY | 5.8 Million USD | 114.81% |
| 1996 Q1 | 800 Thousand USD | 60.0% |
| 1996 Q2 | 700 Thousand USD | -12.5% |
| 1996 FY | 2.7 Million USD | 145.45% |
| 1996 Q4 | 400 Thousand USD | -50.0% |
| 1996 Q3 | 800 Thousand USD | 14.29% |
| 1995 FY | 1.1 Million USD | 120.0% |
| 1995 Q1 | 1.6 Million USD | 14.29% |
| 1995 Q4 | 500 Thousand USD | 600.0% |
| 1995 Q3 | -100 Thousand USD | -105.56% |
| 1995 Q2 | 1.8 Million USD | 12.5% |
| 1994 Q2 | 100 Thousand USD | 0.0% |
| 1994 Q3 | 100 Thousand USD | 0.0% |
| 1994 Q4 | 1.4 Million USD | 1300.0% |
| 1994 FY | 500 Thousand USD | 400.0% |
| 1994 Q1 | 100 Thousand USD | 0.0% |
| 1993 Q4 | - USD | -100.0% |
| 1993 Q3 | 100 Thousand USD | 0.0% |
| 1993 Q2 | 100 Thousand USD | 0.0% |
| 1993 Q1 | 100 Thousand USD | 0.0% |
| 1993 FY | 100 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| American Bio Medica Corporation | -193 Thousand USD | 106.218% |
| Arrayit Corporation | 2.57 Million USD | 99.534% |
| Atlantic International Corp. | -154.23 Thousand USD | 107.78% |
| Biocept, Inc. | -2.58 Million USD | 100.465% |
| Bioqual, Inc. | 7.42 Million USD | 99.838% |
| CardioGenics Holdings Inc | - USD | -Infinity% |
| DermTech, Inc. | 276 Thousand USD | 95.652% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 6.73 Billion USD | 100.0% |
| HTG Molecular Diagnostics, Inc. | 1.79 Million USD | 99.331% |
| iMD Companies, Inc. | -23.63 Thousand USD | 150.768% |
| IDenta Corp. | 662.97 Thousand USD | 98.19% |
| Interpace Biosciences, Inc. | 23.04 Million USD | 99.948% |
| Integrative Health Technologies, Inc. | 77.57 Thousand USD | 84.53% |
| InVitro International | 635.98 Thousand USD | 98.113% |
| Lumos Diagnostics Holdings Limited | 6.56 Million USD | 99.817% |
| Many Bright Ideas Technologies Inc. | - USD | -Infinity% |
| Medical Imaging Corp. | 1.09 Million USD | 98.902% |
| Optigenex Inc. | -102.96 Thousand USD | 111.654% |
| PharmChem, Inc. | 3.9 Million USD | 99.693% |
| Proteome Sciences plc | 2.09 Million USD | 99.428% |
| Response Genetics, Inc | 3.94 Million USD | 99.696% |
| Rennova Health, Inc. | 6.26 Million USD | 99.809% |
| RushNet, Inc. | 1.1 Million USD | 98.914% |
| ScreenPro Security Inc. | 856.57 Thousand USD | 98.599% |
| Stella Diagnostics Inc. | - USD | -Infinity% |
| StageZero Life Sciences Ltd. | -403.74 Thousand USD | 102.972% |
| Todos Medical Ltd. | 4.31 Million USD | 99.722% |